{"entity":{"id":"nct05886920","kind":"trial","name":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","aka":[],"tldr":"A phase 1/2 trial of D3S-002 in advanced solid tumours, run by D3 Bio (Wuxi) Co., Ltd, now recruiting.","summary":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations is a phase 1/2 interventional study registered as NCT05886920 by D3 Bio (Wuxi) Co., Ltd, with 67 participants planned, started 2023-07-10 and due to reach its primary completion in 2028-08. Interventions recorded: D3S-002 and D3S-001.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05886920","url":"https://clinicaltrials.gov/study/NCT05886920"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05886920","phase":"1/2","setting":"A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","sponsor":"D3 Bio (Wuxi) Co., Ltd","enrolled":67,"outcomes":[]},"route":"/trials/nct05886920/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}